This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n20http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023736%3A_____%2F13%3A00010697%21RIV14-MZ0-00023736/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n10http://linked.opendata.cz/resource/domain/vavai/subjekt/
n9http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023736%3A_____%2F13%3A00010697%21RIV14-MZ0-00023736
rdf:type
n9:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.2174/1871529X11313010003
dcterms:description
Multiple myeloma (MM) remains an incurable disease, at least for the big majority of patients, in spite of the great progress with new drugs in the last years. New treatment strategies are needed to improve the outcome of patients. At least, five proteasome inhibitors of the next generation with greater efficacy (carfilzomib, marizomib (salinosporamide A, NPI-0052), threonine boronic acid-derived proteasome inhibitor CEP-18770, the peptide-semicarbazone S-2209, the tripeptide mimetic BSc2118, and MLN9708/2238) have been recently tested in preclinical models of MM. Carfilzomib has been recently approved for the treatment of patients with MM who have received at least two prior therapies, including bortezomib and immunomodulatory derivatives (IMiDs, thalidomide, lenalidomide or pomalidomide). Multiple myeloma (MM) remains an incurable disease, at least for the big majority of patients, in spite of the great progress with new drugs in the last years. New treatment strategies are needed to improve the outcome of patients. At least, five proteasome inhibitors of the next generation with greater efficacy (carfilzomib, marizomib (salinosporamide A, NPI-0052), threonine boronic acid-derived proteasome inhibitor CEP-18770, the peptide-semicarbazone S-2209, the tripeptide mimetic BSc2118, and MLN9708/2238) have been recently tested in preclinical models of MM. Carfilzomib has been recently approved for the treatment of patients with MM who have received at least two prior therapies, including bortezomib and immunomodulatory derivatives (IMiDs, thalidomide, lenalidomide or pomalidomide).
dcterms:title
Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma
skos:prefLabel
Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma
skos:notation
RIV/00023736:_____/13:00010697!RIV14-MZ0-00023736
n9:predkladatel
n10:ico%3A00023736
n3:aktivita
n4:I n4:P
n3:aktivity
I, P(NT13836)
n3:cisloPeriodika
1
n3:dodaniDat
n11:2014
n3:domaciTvurceVysledku
n16:7991401
n3:druhVysledku
n19:J
n3:duvernostUdaju
n14:S
n3:entitaPredkladatele
n20:predkladatel
n3:idSjednocenehoVysledku
109833
n3:idVysledku
RIV/00023736:_____/13:00010697
n3:jazykVysledku
n17:eng
n3:klicovaSlova
apoptosis; IkBalpha; MEK/MAPK; multiple myeloma; NF-kappaB; PI3K/akt/mTOR
n3:klicoveSlovo
n7:NF-kappaB n7:MEK%2FMAPK n7:PI3K%2Fakt%2FmTOR n7:multiple%20myeloma n7:IkBalpha n7:apoptosis
n3:kodStatuVydavatele
NL - Nizozemsko
n3:kontrolniKodProRIV
[E18DDE71BE8F]
n3:nazevZdroje
Cardiovascular & hematological disorders drug targets
n3:obor
n12:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
1
n3:projekt
n18:NT13836
n3:rokUplatneniVysledku
n11:2013
n3:svazekPeriodika
13
n3:tvurceVysledku
Fuchs, Ota
s:issn
1871-529X
s:numberOfPages
18
n13:doi
10.2174/1871529X11313010003